CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0516 (clinicaltrials.gov NCT No: NCT01253460)
Title:A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH
Principal Investigator:William G. Wierda
Treatment Agent:Cyclophosphamide; Rituximab; Sapacitabine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if sapacitabine given in
combination with 2 standard drugs (cyclophosphamide and rituximab) can help to
control CLL and SLL. The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Cyclophosphamide
Rituximab
Sapacitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Cyclacel
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
Dept:Leukemia
For Clinical Trial Enrollment:713-745-0428
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults